BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk

Reuters12-03

BRIEF-<a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> Stockholders Approve Acquisition By <a href="https://laohu8.com/S/NVO">Novo Nordisk</a>

Dec 3 (Reuters) - Akero Therapeutics Inc AKRO.O:

AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING

Source text: [ID:n0001140361-25-044131]

Further company coverage: AKRO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588404050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588404050","market":"us","top_or_hot":-1,"title":"BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Stockholders Approve Acquisition By <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> </title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKRO.O</span>:</p><ul><li><p>AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING</p></li></ul><p>Source text: [ID:n0001140361-25-044131]</p><p>Further company coverage: <span>AKRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 23:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Stockholders Approve Acquisition By <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> </title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKRO.O</span>:</p><ul><li><p>AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING</p></li></ul><p>Source text: [ID:n0001140361-25-044131]</p><p>Further company coverage: <span>AKRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90FN:1","article_id":"2588404050","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588404050","pubTimestamp":1764777008,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk Dec 3  - Akero Therapeutics Inc AKRO.O:AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILINGSource text: [ID:n0001140361-25-044131]Further company coverage: AKRO.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4505":"高瓴资本持仓","AKRO":"Akero Therapeutics"},"translate_title":"简介-Akero Therapeutics股东批准诺和诺德收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9},"content_text":"BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk Dec 3 (Reuters) - Akero Therapeutics Inc AKRO.O:AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILINGSource text: [ID:n0001140361-25-044131]Further company coverage: AKRO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588404050","isCrawlerRequest":true}